Corvex, Inc.
Business
Movano Inc. is developing a platform that brings medical-grade, high-quality biometric data to consumer health devices to enable preventative care and clinical monitoring. It offers wearable products including the Evie Ring (consumer wellness) and the FDA-cleared EvieMED Ring (prescription medical device), a mobile app, cloud analytics, and a patented RF-enabled System-on-a-Chip designed for non-invasive continuous glucose and cuffless blood pressure monitoring. Its activities span product development, clinical studies, regulatory submissions, intellectual property and manufacturing partnerships. It sells direct-to-consumer online, via prescription to healthcare providers and payors, and pursues OEM, VAR and clinical trial channels domestically and internationally.
Summary from filing dated 2025-04-09
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 433,000 | 1 | — | — | — | |
| Cost of revenue | 2 | 3 | — | — | — | |
| Research and development | 6 | 11 | 17 | 19 | 13 | |
| Sales, general and administrative | 8 | 11 | 13 | 11 | 6 | |
| Total costs and expenses | 16 | 25 | 30 | — | — | |
| Loss from operations | −16 | −24 | −30 | −30 | −20 | |
| Interest expense (related party) | −3 | — | — | — | — | |
| Interest and other income, net | 183,000 | 495,000 | 407,000 | — | — | |
| Other income (expense), net | −3 | 495,000 | 407,000 | 133,000 | — | |
| Net loss and total comprehensive loss | −18 | −24 | −29 | −30 | −22 | |
| Cumulative dividends on Series A preferred stock | −37,000 | — | — | — | — | |
| Net loss - attributed to common stockholders | −18 | −24 | — | −30 | −24 | |
| Net loss per share, basic (in Dollars per share) | −21.79 | −39.39 | −9.51 | −0.92 | −0.92 | |
| Net loss per share, diluted (in Dollars per share) | −21.79 | −39.39 | −9.51 | −0.92 | −0.92 | |
| Weighted average shares used in computing net loss per share, basic (in Shares) | 840,720 | 602,333 | 3 | 33 | 26 | |
| Weighted average shares used in computing net loss per share, diluted (in Shares) | 840,720 | 602,333 | 3 | 33 | 26 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 8 | 6 | 11 | 18 | |
| Payroll tax credit, current portion | 107,000 | 52,000 | 450,000 | 379,000 | 166,000 | |
| Vendor deposits | 44,000 | 28,000 | 399,000 | 103,000 | — | |
| Inventory | 2 | 2 | 1 | — | — | |
| Prepaid expenses and other current assets | 243,000 | 362,000 | 442,000 | 405,000 | 1 | |
| Total current assets | 5 | 10 | 9 | 12 | 35 | |
| Property and equipment, net | 101,000 | 213,000 | 342,000 | 443,000 | 529,000 | |
| Right-of-use asset | 415,000 | 600,000 | — | — | — | |
| Other assets | 97,000 | 117,000 | 387,000 | 487,000 | 48,000 | |
| Total assets | 6 | 11 | 9 | 13 | 36 | |
| Accounts payable | 3 | 2 | 3 | 557,000 | 311,000 | |
| Deferred revenue | 12,000 | 36,000 | 1 | — | — | |
| Other current liabilities | 936,000 | 1 | 2 | 4 | 3 | |
| Total current liabilities | 9 | 3 | 6 | 5 | 3 | |
| Other noncurrent liabilities | 267,000 | 520,000 | 50,000 | 214,000 | 36,000 | |
| Total noncurrent liabilities | 267,000 | 520,000 | 73,000 | 350,000 | 317,000 | |
| Total liabilities | 9 | 4 | 6 | 5 | 4 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized at December 31, 2025 and 2024; 3,000 and no shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized at December 31, 2025 and 2024; 904,486 and 684,029 shares issued and outstanding at December 31, 2025 and 2024, respectively | 10,000 | 10,000 | 6,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 163 | 155 | 128 | 103 | 98 | |
| Accumulated deficit | −166 | −148 | −124 | −95 | −65 | |
| Total stockholders' equity (deficit) | −3 | 7 | 3 | 8 | 33 | |
| Total liabilities and stockholders' equity (deficit) | 6 | 11 | 9 | 13 | 36 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 149,000 | 166,000 | 158,000 | 147,000 | 74,000 | |
| Stock-based compensation | 3 | 3 | 3 | 3 | 2 | |
| Noncash lease expense | −1,000 | 246,000 | 224,000 | −13,000 | — | |
| Write-down of inventory to net realizable value | 785,000 | — | — | — | — | |
| Amortization of debt discount (related party) | 3 | — | — | — | 772,000 | |
| Interest expense on bridge loan (related party) | 82,000 | — | — | — | — | |
| Non-cash compensation related to common stock warrants issued to strategic advisory group | — | 60,000 | — | — | — | |
| Loss on disposal of property and equipment | — | 2,000 | 13,000 | 44,000 | — | |
| Payroll tax credit | −55,000 | 567,000 | 427,000 | −250,000 | — | |
| Inventory | −505,000 | −932,000 | −1 | — | — | |
| Prepaid expenses, vendor deposits and other current assets | 103,000 | 451,000 | −209,000 | 788,000 | — | |
| Other assets | −17,000 | −14,000 | — | −50,000 | −38,000 | |
| Accounts payable | 1 | −1 | 3 | 246,000 | 65,000 | |
| Deferred revenue | −24,000 | −1 | 1 | — | — | |
| Other current and noncurrent liabilities | −596,000 | −265,000 | −3 | 1 | — | |
| Net cash used in operating activities | −11 | −23 | −26 | −25 | −16 | |
| Purchases of property and equipment | — | −8,000 | −64,000 | −105,000 | −565,000 | |
| Net cash used in investing activities | — | −8,000 | −64,000 | 16 | −17 | |
| Proceeds from bridge loan (related party) | 2 | — | — | — | — | |
| Proceeds from sale of Series A preferred stock | 3 | — | — | — | — | |
| Issuance of common stock, pre-funded warrants and common stock warrants in April 2024 sale, net of issuance costs | — | 23 | 7 | — | — | |
| Issuance of common stock, net of issuance costs | 2 | 2 | 3 | 2 | 76,000 | |
| Issuance of common stock upon exercise of stock options | 87,000 | 15,000 | 109,000 | 31,000 | — | |
| Net cash provided by financing activities | 6 | 24 | 22 | 2 | 45 | |
| Net increase/(decrease) in cash and cash equivalents | −5 | 2 | −5 | −7 | 12 | |
| Cash paid for interest | 4,000 | — | — | — | — | |
| Cash paid for taxes | — | — | — | — | — | |
| Vesting of common stock issued upon early exercise | — | 23,000 | 113,000 | 145,000 | 136,000 | |
| Issuance of common stock warrants in April 2024 sale | — | 9 | — | — | — | |
| Right of use asset recorded for operating lease liability | — | 544,000 | 50,000 | — | — | |
| Original issue discount on bridge loan | 3 | — | — | — | — | |
| Issuance costs on bridge loan (related party) recorded in accounts payable | 10,000 | — | — | — | — | |
| Accrued interest on bridge loan (related party) in other current liabilities | 72,000 | — | — | — | — | |
| Amortization of original issue discount on bridge loan (related party) | 3 | — | — | — | — | |
| Costs (in equity) related to sale of Series A preferred stock recorded in accounts payable | 150,000 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Corvex, Inc.'s CIK number?
Corvex, Inc.'s SEC CIK number is 0001734750 (1734750). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Corvex, Inc.'s SEC filings?
All of Corvex, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Corvex, Inc. last report earnings?
Corvex, Inc. (MOVE) most recently filed an earnings 8-K with the SEC on May 19, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-059003). This is Corvex, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Corvex, Inc.'s most recent earnings 8-K?
Corvex, Inc.'s latest earnings 8-K (Item 2.02) was filed May 19, 2026 under accession 0001213900-26-059003. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Corvex, Inc.'s latest earnings 8-K →
Look up any company's CIK number →